SCHEMBL134909

SCHEMBL134909

Nc1nc(C(=O)c2ccccc2)nc2nc[nH]c12

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDPK1 O15530 1/20 0.49
GDA Q9Y2T3 1/20 0.49
CDK2 P24941 3/20 0.44
CDK1 P06493 3/20 0.44
CCNB1 P14635 2/20 0.44
MGMT P16455 2/20 0.44
CCNA2 P20248 2/20 0.44
CCNA1 P78396 2/20 0.44
BRD4 O60885 1/20 0.43
KDR P35968 1/20 0.43
AURKB Q96GD4 1/20 0.43
ADORA3 P0DMS8 2/20 0.42
ADORA2A P29274 2/20 0.42
ADORA1 P30542 2/20 0.42
ENPP1 P22413 1/20 0.41
LMNA P02545 3/20 0.40
ALDH1A1 P00352 2/20 0.40
HPGD P15428 2/20 0.40
HTT P42858 2/20 0.40
RAB9A P51151 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6046937 0.83 BRD4 (0.48) PDPK1GDACDK2BRD4ADORA3
SCHEMBL1684049 0.82 GDA (0.58) PDPK1GDACDK2MGMTKDR
SCHEMBL29509029 0.82 GDA (0.58) PDPK1GDACDK2MGMTKDR
SCHEMBL30107648 0.80 GDA (0.56) PDPK1GDACDK2MGMTKDR
SCHEMBL8446397 0.79 BRD4 (0.64) PDPK1BRD4RAB9ANPC1POLB
SCHEMBL27461919 0.79 GDA (0.58) PDPK1GDACDK2MGMTKDR
SCHEMBL5694207 0.78 PDPK1 (0.43) PDPK1GDACDK2CDK1CCNB1
SCHEMBL3630347 0.77 GDA (0.56) PDPK1GDACDK2CDK1CCNB1
SCHEMBL8930240 0.77 ABL1 (0.39) CDK2CCNA2BRD4ALDH1A1HPGD
SCHEMBL4845432 0.77 CDK2 (0.53) PDPK1GDACDK2CDK1CCNB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 940 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11987599-B2 Solid support for synthesizing nucleic acid sequences and methods for making and using UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2024-05-21 US claimed
CN-117924393-A Monomer of 3' -mercapto nucleoside analogue and its synthesis process 天津兴博润生物制药有限公司 2024-04-26 CN claimed
US-20230271998-A1 SOLID SUPPORT FOR SYNTHESIZING NUCLEIC ACID SEQUENCES AND METHODS FOR MAKING AND USING UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2023-08-31 US claimed
US-20220195497-A1 HYBRIDIZING all-LNA OLIGONUCLEOTIDES ROCHE DIAGNOSTICS OPERATIONS, INC. 2022-06-23 US claimed
EP-3980554-A1 HYBRIDIZING ALL-LNA OLIGONUCLEOTIDES F. Hoffmann-La Roche AG (CH) 2022-04-13 EP claimed
CN-113939599-A Hybrid all-LNA oligonucleotides 豪夫迈·罗氏有限公司 2022-01-14 CN claimed
WO-2022005988-A2 SOLID SUPPORT FOR SYNTHESIZING NUCLEIC ACID SEQUENCES AND METHODS FOR MAKING AND USING UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2022-01-06 WO claimed
WO-2020245377-A1 HYBRIDIZING ALL-LNA OLIGONUCLEOTIDES F. HOFFMANN-LA ROCHE AG (CH) 2020-12-10 WO claimed
EP-3004131-B1 PHOSPHORAMIDITE BUILDING BLOCKS FOR SUGAR-CONJUGATED OLIGONUCLEOTIDES AM CHEMICALS LLC (US) 2020-07-22 EP claimed
EP-3119789-A1 BICYCLIC CARBOCYCLIC NUCLEOSIDES AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM Ionis Pharmaceuticals, Inc. (US) 2017-01-25 EP claimed
EP-0747389-A1 3'-SUBSTITUTED NUCLEOSIDE DERIVATIVES TAIHO PHARMACEUTICAL CO., LTD. (JP) 1996-12-11 EP claimed
WO-1996019478-A1 6'-SUBSTITUTED CARBOCYCLIC NUCLEOSIDES NOVARTIS AG (CH) 1996-06-27 WO claimed
WO-1995029930-A2 IMPROVED METHOD FOR OLIGONUCLEOTIDE ANALOG SYNTHESIS GILEAD SCIENCES, INC. (US) 1995-11-09 WO claimed
EP-0570514-A4 METHYLENE PHOSPHONATE NUCLEOSIDE ANALOGS AND OLIGONUCLEOTIDE ANALOGS MADE THEREFROM GILEAD SCIENCES INC (US) 1994-08-17 EP claimed
WO-1994001445-A1 BASE-PROTECTED NUCLEOTIDE ANALOGS WITH PROTECTED THIOL GROUPS RESEARCH CORPORATION TECHNOLOGIES, INC. (US) 1994-01-20 WO claimed
EP-0570514-A1 METHYLENE PHOSPHONATE NUCLEOSIDE ANALOGS AND OLIGONUCLEOTIDE ANALOGS MADE THEREFROM GILEAD SCIENCES, INC. (US) 1993-11-24 EP claimed
WO-1992013869-A1 METHYLENE PHOSPHONATE NUCLEOSIDE ANALOGS AND OLIGONUCLEOTIDE ANALOGS MADE THEREFROM GILEAD SCIENCES, INC. (US) 1992-08-20 WO claimed
WO-1992011276-A1 NOVEL SYNTHESIS OF 2'-'UP' FLUORINATED 2''-DEOXY-ARABINOFURANOSYLPURINES SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) 1992-07-09 WO claimed
EP-0121112-B1 2'-DEOXY-3-PHOSPHONYLMETHYL NUCLEOSIDES AND METHOD FOR THEIR PREPARATION Gesellschaft für Biotechnologische Forschung mbH (GBF) (DE) 1987-05-13 EP claimed
EP-0121112-A1 2'-Deoxy-3-phosphonylmethyl nucleosides and method for their preparation Gesellschaft für Biotechnologische Forschung mbH (GBF) (DE) 1984-10-10 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11987599-B2 Solid support for synthesizing nucleic acid sequences and methods for making and using RNGTT, NSUN2, POLN PDPK1 4243/4885GDA 264/4885CDK2 716/4885
US-20230271998-A1 SOLID SUPPORT FOR SYNTHESIZING NUCLEIC ACID SEQUENCES AND METHODS FOR MAKING AND USING RNGTT, NSUN2, POLN PDPK1 4243/4885GDA 264/4885CDK2 716/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.